Influence of trifluoperazine on platelet aggregation and disaggregation

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Calmodulin activates platelet phospholipase A2, initiating arachidonic acid metabolism.
• Trifluoperazine (stelazine) selectively binds calmodulin and inhibits calcium-induced phospholipase activity.

Purpose of the Study:

• To evaluate the effect of stelazine on human platelet aggregation, disaggregation, and reaggregation.
• To investigate the mechanism of stelazine's action on platelet responses to agonists.

Main Methods:

• Assessing platelet aggregation, disaggregation, and reaggregation in response to various agonists.
• Measuring cyclic AMP (cAMP) levels and release of labeled arachidonic acid.
• Investigating the effects of epinephrine on stelazine-treated platelets.

Main Results:

• Stelazine selectively inhibits the second wave of platelet aggregation.
• Stelazine induces dissociation of platelet clumps and a refractory state in dispersed platelets.
• Epinephrine reverses the refractory state and potentiates responses to thrombin, arachidonate, and A23187.
• Stelazine elevates cAMP levels and inhibits thrombin-induced arachidonic acid release.

Conclusions:

• Stelazine is a selective inhibitor of platelet aggregation's second phase.
• Epinephrine counteracts stelazine's effects, potentially via alpha-adrenergic mechanisms or modulation of calcium and phospholipid metabolism.
• These findings offer insights into platelet activation pathways and potential therapeutic targets.